Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent ...

CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the ...

No sooner did Moderna (MRNA) and Merck & Co. (MRK) announce additional positive data for their cancer vaccine candidate, a messenger RNA (mRNA)-based individualized neoantigen therapy (INT), than ...

Moderna and Merck reported data regarding their cutting-edge mRNA-based skin cancer regimen that includes the former’s cancer vaccine, MRNA-4157. This mRNA-based skin cancer regimen represents one of ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the afternoon session after the broader biotech sector experienced a strong rebound, lifting shares of companies within the industry.

FDA was considering reviewing them simultaneously for a side-by-side comparison. The Food and Drug Administration will hold meetings to review vaccines for children under 5 in June, it announced ...

Moderna MRNA and Merck MRK announced new data for individualized neoantigen therapy mRNA-4157 on Monday at the annual meeting of the American Society of Clinical Oncology that was consistent with our ...

Leading vaccine makers Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) on Wednesday responded to President Donald Trump’s recent criticism that drug companies have yet to justify the success of their ...

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, ...

New data indicate Moderna’s Covid bivalent booster may be more effective against currently circulating Omicron variants of the virus than its original vaccine, the company said Monday. Like data ...

A COVID-19 booster targeting two versions of the coronavirus in one shot offered stronger and broader protection than the current booster, which targets only one version, according to clinical trial ...